MRNA Free Cash Flow
Operating cash flow less capital expenditures — the cash a business keeps after funding itself.
Free Cash Flow
Latest: −$563M (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | −$1.34B |
| 2023Q2 | −$1.15B |
| 2023Q3 | −$1.74B |
| 2023Q4 | $402M |
| 2024Q1 | −$1.19B |
| 2024Q2 | −$1.46B |
| 2024Q3 | −$1.72B |
| 2024Q4 | $303M |
| 2025Q1 | −$1.15B |
| 2025Q2 | −$922M |
| 2025Q3 | −$880M |
| 2025Q4 | $891M |
| 2026Q1 | −$692M |
| 2026Q2 | −$563M |
Other MRNA Charts
More quarter-by-quarter fundamentals for Moderna, Inc.
1 / 10
Revenue
EPS
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Free Cash Flow
Free Cash Flow
Free Cash Flow
Latest Free Cash Flow: −$563M (2026Q2); +38.9% YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, Free Cash Flow ranged from −$1.74B in 2023Q3 to $891M in 2025Q4.